BioMarin to Present at the Morgan Stanley Global Healthcare Conference

NOVATO, Calif., Sept. 7, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 14, 2011 at 10:55 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:


Investors

Media

Eugenia Shen

Bob Purcell

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 506-6570

(415) 506-3267



SOURCE BioMarin Pharmaceutical Inc.

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.